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ABSTRACT 
Objective: The aim of the present study was to develop in-situ gelling formulations of Fluconazole (FCZ) using thermosensitive polymer for 
treatment of vaginal Candidiasis. 
Methods: In-situ gelling formulations of FCZ (1 % w/w) were prepared with different concentrations of Poloxamer 407 (P 407, 15-20% w/w) using 
the cold dispersion method. Similarly,  formulations were also prepared by adding mucoadhesive polymers like hydroxyethyl cellulose, 
Polycarbophil, Carbopol 974 and Hydroxypropyl methylcellulose E 50 LV (0.4 % w/w) to the P 407 formulations. These formulations were 
evaluated for appearance, clarity, pH, gelling ability, gelling time, gelling temperature, viscosity (in sol and gel forms), spreading time, ex-vivo 
mucoadhesion, in-vitro dissolution, morphological characteristics by SEM and in-vitro antifungal efficacy against Candida albicance. In-vivo vaginal 
irritation of developed formulation was assessed in New Zealand female rabbits.  
Results: In-situ gelling formulation of FCZ, prepared using 18 % w/w P407 and 0.4 % hydroxyethyl cellulose, was optimized since this formulation 
was found to be clear, transparent, forming a quick and stable gel with shear thinning behaviour and excellent mucoadhesion. The developed 
formulation released 74.21% of FCZ after 8 h of dissolution in 5.2 pH citrate buffer. In-vitro antifungal activity against Candida albicance showed the 
stronger antifungal activity of formulation as compared to a marketed formulation. In-vivo vaginal irritation study in rabbits demonstrated no 
significant irritation after 10 d of exposure to the formulation.  
Conclusion: The study demonstrated that in-situ gelling formulation of FCZ prepared using thermosensitive polymer had improved activity against 
Candida albicance and would be efficacious for the treatment of vaginal Candidiasis. 
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INTRODUCTION 
Vaginal route of drug delivery is gaining the attention of scientists in 
recent years due to its unique features including, large surface area, 
high perfusion rate, the feasibility of uterine drug targeting and good 
permeability of many drugs [1]. The potential of the vaginal route 
has been investigated for local as well as systemic delivery of drugs, 
especially microbicides [2], contraceptives [3, 4], anticancer drugs 
[5] anti-infectives [6], drugs used for hormone replacement therapy 
[7] and mucosal vaccination [8]. Despite all the advantages of the 
vaginal route, the factors like vaginal secretions, pH, microflora and 
cyclic changes need to be considered during development of vaginal 
formulations [9, 10].  
For the effective local therapy, the vaginal drug delivery system 
should be easy to administer, distribute in the vaginal cavity, release 
drug in a sustained manner for an extended period of time and 
remain in contact with the vaginal mucosa for prolonged time so as 
to minimize the earlier clearance of the drug [8, 11]. Mucoadhesive 
gels have several advantages over other dosage forms such as 
increase contact with the mucosal surface, cause lubrication of the 
dry vagina, which helps in drug uptake and permeation and does not 
produce irritation to the mucosa. But it may also suffer from the 
limitations like messiness, difficulty in administration and difficulty 
in spreading of gel in the vagina [12]. In the case of vaginal 
infections, the direct application of gels onto the infected sites of the 
vagina might be difficult as well as inconvenient. To overcome this 
problem, recently, in-situ gelling liquid dosage forms have been 
investigated for vaginal delivery [13-16]. These liquids when applied 
to vaginal cavity turn into gels as a result of chemical/physical 
change induced by physiological environments. This transition is 
induced by a shift in pH or temperature as in Poloxamers [17]. 
Poloxamer, a block copolymer made of polyoxyethylene (PEO) and 
polyoxy-propylene (PPO), is known for its excellent compatibility 
with other chemicals, and high solubility capacity for various drug 
[18-20]. At low temperature, both PEO and PPO blocks of the 
Poloxamer are soluble in water. As a result, the PEO-PPO-PEO 
chains exist as unimers and form cage-like structures in water and 
exist as a liquid. At higher temperatures, the cage-like structures 
are broken, and the hydrophobic PPO blocks are exposed. 
Therefore, they can associate to form micelles and thus forms gels 
at higher temperature [21]. 
One of the major drawbacks of Poloxamer is its weak mechanical 
strength which leads to rapid erosion. Considering the anatomy and 
physiology of the vagina, there are chances of Poloxamer gel dilution 
due to the presence of vaginal fluid and continuous mechanical stress 
applied due to squeezing action of elastic vaginal walls leading to 
leakage from vaginal cavity [22]. The blending of Poloxamer with 
other polymers is reported to increase not only the mechanical 
strength of the formulation but also its surface interaction with the 
mucosal tissue and consequently, contact time. To date, the most 
commonly studied mucoadhesive polymers are synthetic poly 
acrylates like carbopols (C 974 and C980), polycarbophil (PC) [1], 
cellulose polymers like Hydroxyethyl cellulose (HEC) [23, 24], 
hydroxyl propyl cellulose (HPC) and Hydroxypropyl methyl cellulose 
(HPMC) [7]. Mucoadhesive polymers are able to swell rapidly when 
placed in the aqueous environment. The polymer chains 
interpenetrate across the mucus layer of the vaginal mucosa, which 
results in adhesion, thus the formulation is retained at the biological 
surface for a longer time and the drug is released in a controlled 
manner close to the absorptive membrane, with a consequent 
enhancement of bioavailability [10, 12].  
In the present study, an attempt has been made to develop and 
evaluate mucoadhesive thermo sensitive in-situ gelling formulations of 
Fluconazole (FCZ) for the treatment of vaginal Candidiasis. FCZ is a 
triazole with a wide spectrum of antifungal activity, high efficacy and is 
comparatively safer as compared to other imidazole derivatives. FCZ 
acts on lanosterol 14-alpha-demethylase and inhibits the synthesis of 
ergosterol, which leads to loss of fluidity and integrity of the fungal cell 
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membrane. Azoles also reduce the adhesion of fungal cells to host 
tissue and reduce multiplication and growth of fungi [25]. In the 
present study, in-situ gel formulations were formulated using 
thermo sensitive polymer, poloxamer 407 and evaluated for clarity, 
gelling time, gelation temperature, and viscosity, spread ability, ex 
vivo mucoadhesion, in-vitro dissolution, in-vitro antifungal efficacy 
and in-vivo vaginal irritation.  
MATERIALS AND METHODS 
Materials 
Fluconazole (FCZ) was a generous gift from IPCA laboratories, Mumbai, 
India. Kolliphor P 407 (P 407) was received from BASF, Mumbai, India. 
Carbopol 974 (C974) and Polycarbophil (PC) were received as gift 
samples from Lubrizol, Mumbai, India. Natrosol 250 (Hydroxyethyl 
cellulose, HEC) and Methocel E50 LV (Hydroxy propyl methyl cellulose, 
low viscosity, HPMC E) were received from Ashland, Mumbai, India and 
Colorcon Asia Pvt Ltd, Mumbai, India respectively. Deionized water and 
the solvents of analytical grade were used for the study.  
Methods 
Preparation of in-situ gelling formulations of FCZ using P407 
In-situ gelling solutions were prepared on weight basis using the 
cold method [26]. The required amount of P s407 (15 to 20 % w/w) 
was dispersed in water containing benzalkonium chloride (0.01 % 
w/w) and 5 % w/w glycerol at 5+3 °C. The partially dissolved P407 
solutions were stored in the refrigerator for 24 h until the complete 
dissolution of the polymer. FCZ (1 % w/w) was dissolved in 10 % 
w/w propylene glycol (PG). This solution was added dropwise to the 
P 407 solution and mixed uniformly to obtain the final formulation 
(table 1). 
For the preparation of in-situ gelling formulations of P 407 with 
mucoadhesive polymers, viz., HEC, HPMC E 50, C 974 and PC, the 
procedure was slightly modified. For the formulations with C 974 
and PC, the required amount of C 974 and PC were dispersed in 
water with continuous mechanical stirring for 1 hour. For HPMC E 
50 and HEC formulations, the polymers were dispersed in the water 
at 80 °C with continuous stirring till the dissolution. To these 
polymer solutions, glycerol, benzalkonium chloride and FCZ solution 
in propylene glycol were added followed by addition of P 407. The 
dispersion was kept for complete solubilization of P 407 at 
refrigerated temperature for 24 to 48 h to obtain in-situ gelling 
formulations (table 1). 
Evaluation of in-situ gelling formulations 
Appearance and clarity 
The formulations were observed carefully for colour, odour and 
presence of suspended particulate matter if any. The clarity of the 
solutions was further assessed by observing them against a dark and 
white background. The formulations were graded as, turbid (-), 
slightly turbid (+), clear and transparent (++). 
  
Table 1: Composition for in-situ gelling formulations of FCZ 
Code P 407 (%w/w) Mucoadhesive polymer (%w/w) PG (%w/w) Glycerol (%w/w) FCZ (%w/w) 
P1 15 - 10 5 1 
P2 16 - 10 5 1 
P3 17 - 10 5 1 
P4 18 - 10 5 1 
P5 19 - 10 5 1 
P6 20 - 10 5 1 
PE 18 0.4 % HEC 10 5 1 
PH 18 0.4 % HPMC E 50 10 5 1 
PC 18 0.4 % C974 10 5 1 
PP 18 0.4 % PC 10 5 1 
*All above formulations contained 0.01% w/w of benzalkonium chloride and distilled water sufficient to make 20 g of solution. 
 
Gelling ability [27] 
The formulations (0.5 ml) were slowly added into 2 ml of citrate 
buffer pH 5.2 (37±1 °C) contained in glass vials without shaking. The 
transition of the formulation to viscous gel was observed visually, 
and numerical scores were assigned depending upon the quickness 
of gel formation and time taken for the collapse of gel structure on 
shaking the vials. The formulations were graded as, No Phase 
transition (-), Formation of gel after 60 S and collapsed rapidly 
within 1 h (+), Formation of gel after 60 S and gel collapsed within 3 
h (++), Formation of gel within 60 S and gel remained stable for 
more than 6-7 h (+++). The average of three readings was recorded. 
Gelling temperature [28] 
2 ml of the formulation was placed in a test tube which was 
immersed in a cryostatic water bath (Modern scientific, MIC 1500, 
India) at 4 °C. The temperature of the bath was gradually increased 
with the increment of 1 °C. The sample is allowed to equilibrate at 
each temperature. The sample was observed by tilting the test tube 
by an angle of 90 °. The temperature at which sol to gel transition 
took place was noted as gelation temperature and was indicated 
when meniscus would no longer move after tilting the test tube. The 
experiment was repeated in triplicate and average of three readings 
was taken. 
Spread ability [29]  
For determining the spread ability of in-situ gelling formulations, a 
specially fabricated apparatus was used. The apparatus consisted of 
a rectangular glass slide mounted on a triangular glass box making 
an angle of 45 ° to the horizontal surface. The temperature of the 
glass slide was maintained at 37 °C. One drop of the formulation was 
placed on the slanting glass slide and the distance travelled by the 
drop before getting gelled was noted as spreading time. 
Viscosity [30] 
The viscosity of the liquid formulations (at 10 °C) as well as of the 
preformed gels (at 37 °C) was determined using programmable 
Viscometer (Brookfield, RVDV pro II, USA). For determination of 
solution viscosity, 5 ml of formulation was transferred into the sample 
cell which was placed carefully within a small volume sample adaptor. 
The guard leg was placed around the adaptor, and the sample was 
continuously stirred. The viscosity of the sample was measured at 
different RPM ranging from 0.5 to 100 RPM at temperature 10 °C. For 
the determination of viscosity of gel at 37 °C, the formulations were 
equilibrated at a temperature of 37 °C for 24 h. The viscosity of the gel 
was determined using a Brookfield Viscometer with T-bar spindle. The 
helipad movement was controlled to avoid touching of the spindle to 
any part of the sample holder especially the bottom. A typical run 
involved changing the angular velocity from 0.5 to 100 RPM after 
every 10 s at a controlled speed. The viscosity values at each RPM 
were noted. For the same gel sample, the experiment was repeated 
thrice, and the average reading was noted. 
Effect of dilution on viscosity [31] 
Vaginal formulations after administration might get diluted with the 
vaginal fluid. The dilution of in-situ gel might lead to an early erosion 
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of gel. In order to assess the effect of dilution on the viscosity of the 
gel, 0.25 ml citrate buffer (pH 5.2) was added per 2 g of gel. The 
viscosity of the diluted gel was determined using the Brookfield 
Viscometer. 
Drug content 
1 ml of formulation was diluted to 100 ml with Citrate buffer pH 4.0. 
The solution was filtered, and FCZ content was analysed by a UV 
spectrophotometer (Shimadzu, UV-1700, Japan) at λmax
In-vitro dissolution [32] 
 of 260 nm. 
For each formulation, the experiment was repeated thrice. 
The in-vitro release of FCZ from various formulations was carried 
out using a dialysis tube (Mol size cut off 10000 to 12000 Da). 
Formulation (2 g) was placed into the dialysis tube which was 
previously soaked in citrate buffer pH 5.2. Both the ends of the tube 
were tied, and the tube was placed in a beaker containing 100 ml of 
citrate buffer pH 5.2. The dissolution assembly was further placed in 
a water bath maintained at 37 °C and the content of beaker was 
stirred at 100 RPM. Aliquots (5 ml) were withdrawn from the 
release medium at one h interval and replaced by an equal volume of 
the release medium. The aliquot withdrawn was filtered using 0.45 
µm syringe filters and FCZ content was analysed at 260 nm by the 
UV spectrophotometer. The release experiments were repeated in 
triplicate and average of three readings were recorded. The data 
obtained from release experiments were fitted to the Korsemayer 
Peppas model to find out the mechanism of drug release (table 2).  
M
M
t/M = k tn 
t
Scanning electron microscopy [34] 
/M represents a fraction of drug released at time t, k is release 
constant, and n represents a mechanism of drug release. The value 
of n as 0.5 indicates drug release by Fickian diffusion. The value of n 
between 0.5 to 0.9 indicates non Fickian or anomalous drug release, 
whereas if n = 0.9, it indicates zero order drug release [33].  
To study the changes in the morphology of P 407 gels, after addition 
of mucoadhesive polymers, selected gels were lyophilized 
(Labconco, Free Zone 2.5, USA) and morphological characteristics 
were studied by SEM (JEOL, JSM-6360A, Japan). 
Mucoadhesive strength [35] 
Mucoadhesive properties of in-situ gel formulations were assessed 
using a Texture Analyzer (Brookfield, CT3 Texture Analyzer, USA). A 
sample of goat vaginal tissue was collected immediately after 
slaughter of the animal and was separated from the underlying 
tissues. After proper washing with distilled water, the tissue was 
rapidly frozen (−20 °C) and stored in the de Jalon solution. Before 
testing, vaginal tissue was defrosted at room temperature. The 
tissue was placed on the base of the texture analyser. The gel 
formulations (previously equilibrated at 37 °C) were applied to the 
aluminium probe of Texture Analyzer using double sided adhesive 
tape. The vaginal tissue was moistened with citrate buffer pH 5.2. 
The probe of Texture Analyzer was lowered until contact with tissue 
was made. After establishing the contact for 20 S with contact load 
of 10 g, the probe was withdrawn at a rate of 1 mms−1
In-vitro antifungal activity [34] 
. The force 
required to detach the gels from goat vaginal tissue was measured as 
mucoadhesive strength (g). The readings were taken in triplicate on 
the same vaginal mucosa. 
The antifungal activity of the optimized formulation was evaluated 
against Candida albicance. The viability of Candida in Sabouraud’s 
Dextrose (SD) broth (pH 5.2) was compared with its viability in the 
presence of the developed in-situ gel formulation. Briefly, Candida 
suspension, prepared from a broth culture of Candida albicans, was 
added to a flask containing 100 ml of SD broth (pH 5.2). The final 
strength of Candida was adjusted to 6 log of CFU/ml. Before the 
addition of the formulations, T0 reading was taken. To each flask, 5 g 
of different formulations were added and incubated aerobically at 
37 °c for 24 h. The viable count of Candida was determined at 0 (T0), 
6 (T6) and 24 (T24
Vaginal irritation study 
) hours in triplicate for each flask. Appropriate 
dilutions were plated on SD agar plates and resulting colony forming 
units per ml of the culture was determined and compared against 
control and standard. Candida in SD broth (pH 5.2) was used as a 
control, Marketed gel formulation of FCZ as standard and gel base 
without drug as a solvent control. Statistical analysis was done by 
one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparison tests (Graph pad Instat, version 3.1, USA) 
wherein each test sample was compared with the control.  
Vaginal irritation study of the optimized formulation (PE) was 
performed, using the rabbit as the animal model, in National 
Toxicology Centre, Pune. The study was conducted with prior 
approval from the animal ethical committee as per Committee for 
the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA), India, guidelines. The rabbits were provided with food 
pellets and water ad libitum and temperature and humidity were 
controlled at 20-22 °C and 40-60 % RH respectively. A 12 h 
light/dark cycle was maintained. The study was performed on 6 
female New Zealand white rabbits of weight 2.5 to 3.0 Kg, used in 2 
replicates of 3 rabbits per group. The in-situ gel formulation, PE (0.5 
g), containing 1 % w/w of FCZ, was applied to the vagina of the first 
group of rabbits with a syringe applicator. The placebo formulations 
were applied to the second group of rabbits. The dose of 0.5 g/rabbit 
twice daily was administered for 10 d. The animals were examined 
visually at preselected time intervals for any signs of vaginal or 
vulval irritation. The findings were recorded in terms of the 
numerical scores for each animal on following grades, no irritation 
(0), minimal (1), mild (2), moderate (3), severe (4). The average 
score of six rabbits was considered for determination of any 
irritation by gel formulation. 
RESULT AND DISCUSSION 
Appearance, clarity, pH and drug content 
All the formulations of P407 alone and with non-ionic polymers, 
HPMC E 50 LV and HEC were found to be very clear without any 
precipitation. The formulations containing C 974 and PC were found 
to be slightly turbid initially, but the turbidity disappeared after 
storage of the formulations for 48 h. This might be because C974 and 
PC formed aqueous colloidal dispersions initially, which imparted 
slight turbid appearance to the formulation. After equilibration of 
the formulations, due to complete swelling of the polymer, the 
turbidity disappeared. pH of the formulations was found to be in the 
range of 5.2 to 5.8. This pH range is acceptable to the vaginal cavity 
as the vaginal pH is in the range 4.0 to 5.5 [12]. The drug content of 
formulations was found to be in the range of 94.0+0.34 to 98.6+0.97. 
In-situ gelling ability and gelation temperature of formulations 
An ideal in-situ gelling system should be a free flowing liquid with 
low viscosity at the storage conditions (at 25 °C) to allow 
reproducible administration into the vaginal cavity. It should also 
undergo in-situ phase transition to form a strong gel capable of 
withstanding shear forces in the vaginal cavity and sustain drug 
release at physiological conditions in vaginal fluid (pH 4.0 to 5.5 and 
37 °C). Hence, formulations were evaluated for their in-situ gelling 
ability in citrate buffer pH 5.2 at 37 °C and temperature of sol-gel 
transition was also evaluated. 
The gelation temperature obtained (table 2) for different P 407 
concentrations (15% w/v to 20% w/v) were found to be in 
accordance with the results obtained in the literature [36] and 
confirmed that it was dependent on polymer concentration. It is 
evident from the results that the increase in P 407 concentration 
resulted in a decrease in gelation temperature. The gelation of P 407 
is the result of the formation of cubic micellar structures[37]. 
Poloxamer is made up of PEO and PPO units. PEO units are 
hydrophilic, and PPO units are less hydrophilic. When the 
temperature and concentration of P407 increase above a critical 
point, the less hydrophilic PPO units undergo dehydration. This 
dehydration causes aggregation of PPO units leading to micelle 
formation. The increase in the P407 concentration leads to 
enlargement of micelles and tight packing of adjacent micelles 
leading to gel formation at lower temperatures. The gel is more 
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entangled at higher concentration of P 407 [38, 39]. The formulation 
containing P 407 at concentration 15% w/w (P1) did not form a gel 
at physiological conditions in citrate buffer (pH 5.2; temperature 37 
ºC). This might be attributed to its higher gelation temperature (41 
°C). Formulations with 16 % (P2) and 17% w/w (P3) of P 407 
formed gels after 60 S and the resultant gel collapsed within 1 h and 
3 h respectively. The formulations containing P407 at concentration 
18% w/w (P4) or more were found to be forming gels quickly within 
60 S (gelation temperature equal to or less than 28.2 °C) and had a 
stable gel structure after formation. Hence, for further study, 18% 
w/w concentration of P 407 was considered as optimum. 
When mucoadhesive polymers (HEC, HPMC, C 974 and PC) were 
incorporated in 18% w/w of P 407 formulations, the gel formation 
was quick and gelation temperature was lowered to a significant 
extent. This suggests an increase in the gel strength with the 
addition of these mucoadhesive polymers. It can be assumed that, 
the addition of mucoadhesive polymers might form hydrogen bonds 
with PEO blocks in P 407 solutions, which might cause dehydration 
of P 407 molecules, leading to aggregation of molecules at a lower 
temperature. Thus, sol to gel phase transitions was obtained at 
lower temperature [40]. The addition of C974 and PC reduced the 
gelation temperature drastically, which might be attributed to the 
high hydrophilic interaction of Carbopol with water. Also, the 
carbopol backbone is hydrophobic, which lead to the formation of 
crosslink between hydrophobic chain which subsequently increases 
the viscosity of formulation resulting into a quick sol to gel 
transition [36]. 
  
Table 2: Physical characteristics of in-situ gelling formulations of FCZ 
Code Appearance 














P1 ++ - 40.2+0.2 -- -- -- -- 
P2 ++ - 36.1+0.2 4.5+0.2 0.4928 37.77 0.9903 
P3 ++ + 32.0+0.1 3.5+0.1 0.5028 31.24 0.9759 
P4 ++ ++ 28.2+0.3 3.3+0.2 0.5290 27.75 0.9923 
P5 ++ +++ 26.9+0.2 2.5+0.2 0.5357 25.18 0.9938 
P6 ++ +++ 24.7+0.1 2.0+0.3 0.5820 20.02 0.9880 
PE ++ +++ 27.10.3 2.9+0.1 0.6177 20.44 0.9986 
PH ++ +++ 27.7+0.2 3.1+0.1 0.5421 25.45 0.9970 
PC + ++ 25.9+0.2 2.2+0.2 0.5668 23.14 0.9982 
PP + ++ 25.6+0.1 2.2+0.1 0.5722 23.24 0.9994 
*Appearance and clarity: (-) Turbid, (+) slightly turbid, (++) clear and transparent. **Gelling ability: (-) No phase transition, (+) Formation of gel 
after 60 S and gel collapsed within 1h, (++) Formation of gel after 60 S and gel collapsed within 3 h, (+++) Formation of gel within 60 S and gel 
remained stable for more than 6-7 h. ***Mean+SD, n=3. 
 
Spreadability  
The spreadability of formulations was measured in terms of distance 
travelled by the formulations before the transition to gel. The 
increase in Poloxamer concentration decreased the spreadability of 
the formulations due to a decrease in gelation temperature. The 
addition of mucoadhesive polymers also lowered the spreadability. 
Viscosity 
In-situ gelling systems are expected to undergo shear thinning 
(decrease in viscosity with increasing shear rate) in liquid as well as 
gel state due to the pseudoplastic behaviour of the gels formed. The 
viscosities of FCZ formulations both in solution as well as gel forms 
were determined using a Brookfield Viscometer. The results are 
reported in fig. 1 and fig. 2. 
 
 
Fig. 1: Effect of P 407 concentration on viscosity of gel at 37 °C 
*Average of three readings+SD 
 
Fig. 2: Viscosity of in-situ gelling formulations at 10 °C 
*Average of three readings+SD 
 
The gel form of all the formulations of P 407 was found to be 
exhibiting shear thinning behaviour (decreasing viscosity at 
increasing RPM). It was observed that the viscosity of P 407 
formulations after gelation (at 37 °C) (fig. 1) was much higher than 
that of solution form (10 °C) (fig. 2), suggesting the occurrence of 
phase transition between two conditions. This increase in viscosity 
for P 407 formulations, from non-physiological to physiological 
conditions, was mediated by temperature and was the result of 
micelle formation leading to sol-gel transition. 
It was also observed that as the concentration of P 407 was increased, 
the viscosity of resulting gel was increased. This is because, the 
increase in P 407 concentration resulted in increase micelle size and 
micelle number, thus leading to a decrease in the distance between the 
adjacent micelles. This further leads to increased interaction of the 
micelles resulting information of viscous gels. 
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All the gels were found to be exhibiting shear thinning behaviour 
(decreasing viscosity at increasing RPM). This decrease in viscosity is 
due to the breakdown of three-dimensional network structures due to 
high stress developed because of the high rate of shear. When 
mucoadhesive polymers were added to the P 407 gel, the viscosity of the 
resultant gel was found to be increased (fig. 3). This might be the result 
of the formation of hydrogen bonding between the oxygen atom of PEO 
and hydrogen group of cellulose or poly (acrylic acid) derivatives. This 
increase in hydrogen bonding increased the gel strength and viscosity of 
the resultant formulation to a greater extent [28].  
 
 
Fig. 3: Viscosity of P407 formulations with mucoadhesive 
polymers at 37 °C, *Average of three readings+SD 
 
Effect of dilution on viscosity 
In-situ gelling vaginal formulation is intended to retain its gel 
structure and release the drug in a sustained manner. When the 
formulation is applied to vaginal cavity, there are chances of 
formulation getting diluted with vaginal fluid. Thus, it is required to 
develop a formulation which is insensitive to dilution and be capable 
of releasing the drug in a sustained manner for a prolonged period 
of time. Generally, 2 to 5 g of the formulation is applied to the 
vaginal cavity which might get diluted with 0.25 to 0.5 ml of vaginal 
secretions. Hence, 0.25 ml of citrate buffer (pH 5.2) per 2 g of the 
formulation was added, and viscosity of diluted formulation was 
determined. It was observed that there was a significant dilution of 
18 % P 407 gels, and there was almost 50 % drop in the viscosity 
(fig. 4). This might be due to dilution with buffer, the concentration 
of P 407 in formulation P4 (18 % w/w) decreased to 16 % w/w 
which decreased its viscosity drastically and viscosity resembled the 
viscosity of P2 (16 % w/w) formulation. The drop in the viscosity 
was lower with the addition of mucoadhesive polymer. The 
formulation containing HEC was found to be a more robust 
formulation amongst all the formulations whereas the effect of 
dilution was more pronounced with C 974 and PC. This might be 
because of the presence of unfavourable pH conditions for ionization 
of Carbopol [41]. 
 
 
Fig. 4: Effect of dilution on viscosity of in-situ gelling 
formulations, *n=3, Mean+SD 
In-vitro drug release 
All the formulations showed burst release at the start of the release 
experiment. This might be because of the lag time required for sol to 
gel transition of the formulations. It was observed that there was a 
corresponding decrease in the release of FCZ from the gels with an 
increase in the concentration of P 407 from 16% w/v to 20% w/v 
(P2-P6) (fig. 5). After 0.5 h of dissolution, formulation P4 (18% w/v 
of P 407) released 20.90+1.9 % of FCZ, whereas formulation P6 
(20% w/v of P 407) released 14.93+1.1 % of the drug. This indicated 
a decrease in burst release of drug with an increase in the 
concentration of polymer. At higher concentration of P 407, sol to 
gel transition was quicker, which resulted in a decrease in burst 
release. 
After 8 h of dissolution, formulation P4 (18% w/v of P 407) released 
88.31+0.8 % of FCZ and P6 (20% w/v of P 407) released 75.45+2.0 
% of the drug. The probable mechanism for such retardation of 
release, with the increase in P 407 concentration, may be a reduction 
in number and dimensions of the channels in the gel structure. 
Decrease in the inter-micellar distance within the gel leads to 
bridging between the neighboring micelles and increase in viscosity 
of gels, thus decreasing the drug release [26]. 
 
 




Fig. 6: Release profile of P 407 gel with mucoadhesive polymers 
*n=3, Mean+SD 
 
The addition of mucoadhesive polymer to the formulations led to 
decrease in the release of FCZ (fig. 6). The drug release from P 407 
gel is mainly through extra cellar channels filled with water. The 
presence of mucoadhesive polymer would decrease the amount of 
free water in these channels as well as lead to hydrogen bonding 
with water. This would result in an increase in the viscosity and 
subsequent decrease in the drug release [28]. The release of FCZ 
from formulations containing mucoadhesive polymers was found to 
be in the following order:  
HPMC E 50 LV>PC>C 974>HEC. 
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The faster release from HPMC E 50 formulation was because of 
lower viscosity of the formulation. Although Carbopol and PC 
formulations indicated higher viscosity, the drug release was faster 
from these formulations. This might be attributed to a decrease in 
the viscosity of Carbopol or PC polymer in the presence of 
dissolution medium with pH 5.2. Carbopol requires a favourable pH 
(above 6.0) for ionization of carboxylic group which results in de-
coiling and relaxation of the polymer network, enhancing the 
viscosity of its gel. As pH of the vagina is acidic, at lower 
concentration Carbopol would undergo rapid erosion resulting in a 
higher FCZ release. The release of FCZ was found to be more sustained, 
with Poloxamer-HEC formulation (PE). After 8 h of dissolution, 
formulation PE was found to release 74.21+1.0 % of FCZ. 
Kinetics of drug release 
The mechanism of drug release from gel matrix is complex and is 
based on diffusion of drug through a hydrated portion of the gel matrix 
and erosion of the outer fully hydrated polymer on the surface of the 
matrix. Due to permeation of excess water into the core of gel matrix, 
there is an increase in hydration of gel matrix which provides a 
diffusion barrier to drug release. As gel matrix becomes fully hydrated, 
the polymer chains become completely relaxed and can no longer 
maintain the integrity of the gel leading to disentanglement and 
erosion of polymer from the surface of the gel matrix. 
For P 407 formulations P1 and P2, n value closely approximated to 0.5 
indicating Fickian diffusion (table 2). Thus, the drug release from the 
gel formulation was mostly governed by diffusion of FCZ through a gel 
matrix. With the increase in the P 407 concentration, there was a 
decrease in the rate of drug release and initial burst release. This was 
evident from n value 0.52 to 0.58. The addition of mucoadhesive 
polymers to P 407 also changed the n value to 0.54 to 0.61 which 
indicated non-Fickian/anomalous behaviour. Thus, the drug release in 
these formulations was mostly governed by both drug diffusion 
through gel matrix and disentanglement or erosion of polymer chains. 
 
 
Fig. 7: Scanning electron micrographs of (A) lyophilised P 407 gel (B) lyophilised P 407 with HEC gel 
 
Scanning electron microscopy 
Fig.7 indicates morphological changes that occurred after the 
addition of mucoadhesive polymer to the P 407. The lyophilised P 
407 gel exhibited plate-like structure with a smooth surface, 
whereas the surface of P 407-HEC gel represented more compact 
structure with an irregular surface. The change in the morphology of 
the gel might affect the release of drug from the gel matrix.  
Mucoadhesive strength  
Mucoadhesion relies on the interaction of a polymer and the mucin 
coat covering the vagina. Structurally, the mucin consists of a 
protein or polypeptide core with carbohydrate side chains 
branching off the core. The polymer with many hydrophilic 
functional groups (e. g. carboxyl group, a hydroxyl group and 
sulphate) can establish electrostatic interactions and hydrophobic 
interactions and hydrogen bond with the underlying surface. Of 
these non-covalent forces, hydrogen bonding appears to be the most 
important [42]. The mucoadhesive potential of all gel formulations 
was evaluated by using goat vaginal mucosa (fig. 8).  
 
 
Fig. 8: Mucoadhesive strength of in-situ gels, *Average of three 
readings+SD 
It could be noted that when mucoadhesive polymers were added to P 
407 gel, the adhesion was increased. The increase was significant with 
the addition of HPMC and HEC. This can be attributed to the 
interaction of hydroxyl group of cellulose derivatives with a 
hydroxyl/carboxyl group of mucin leading to the formation of 
hydrogen bonds between gel formulation and mucous membrane. 
This might have resulted in an increase in mucoadhesion. Thus, 
indicating the chances of prolonged retention of formulation on 
vaginal mucosa. 
Considering the results of mucoadhesion and in-vitro drug release 
from various formulations, PE formulation with HEC as mucoadhesive 
polymer was selected as optimized formulation for further study. 
 
 
Fig. 9: Comparison of antifungal in-vitro activity of developed 
formulations with the marketed formulation. *n=3, Mean+SD 
 
In-vitro antifungal activity 
The viability of Candida albicance in the presence and absence of the 
developed formulation was evaluated after 6 h and 24 h of 
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incubation and shown in fig. 9. The data in fig. 9 is represented as 
the average of three observations with a standard error mean (* 
indicates p<0.05 and ** p<0.01, NS–non significant). The cell count 
of Candida was found to be decreased with marketed formulation, 
(p<0.01) after 6 h (5.88+0.11 log cfu/ml) and 24 h (5.39+0.10 log 
cfu/ml) of incubation (survival 89.83 %) as compared to T0
In-vivo vaginal irritation study 
 reading 
(6+0.1 log cfu/ml). The developed formulation (PE) exhibited strong 
antifungal activity (**p<0.01) with a reduction in the Candida count 
at 6 h (5.60+0.16) and 24 h (3.47+0.22) with the survival of 57.8 % 
of Candida. Thus, the study suggested that the developed in-situ 
gelling formulation showed inhibitory activity against Candida. This 
showed the possibility of the developed formulation to be used for 
effective treatment of Candidiasis. 
The rabbit model was selected for vaginal irritation study since the 
vaginal epithelium of rabbit is columnar which is very sensitive, 
hence considered to be the standard model for irritation study. After 
application of developed drug loaded formulation and placebo 
formulation for 10 d, there was no sign of irritation on the vulval or 
vaginal region of the rabbit as evident from the average score 
assigned as 0. Thus, the developed formulation was found to be safe 
for vaginal application. 
CONCLUSION 
In this study, an in-situ forming gel of FCZ for vaginal delivery was 
formulated using a combination of P 407 and HEC. The developed 
formulation was clear, spreadable, with shear thinning properties, 
forming a quick and stable gel having resistance to dilution and 
excellent mucoadhesion to the goat vaginal mucosa. The formulation 
exhibited sustained release behaviour and indicated strong antifungal 
activity against Candida albicance. The formulation did not cause 
irritation to vaginal mucosa when tested on the rabbit. Thus, the study 
demonstrated the potential of thermosensitive polymer in vaginal 
delivery of FCZ for effective treatment of vaginal Candidiasis. 
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